XL888 was one of the top hits in the initial HTS, and we were able to validate its potency in deleting p16Ink4a+ fibroblasts in both a preclinical model of murine lung fibrosis as well as PCLS of IPF lung tissue. Here, CDKN2A is linked to pulmonary fibrosis.